First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis.
Fiche publication
Date publication
octobre 2014
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CHAIGNEAU Loïc, Dr MENEVEAU Nathalie, Pr NERICH Virginie, Pr PIVOT Xavier
Tous les auteurs :
Nerich V, Chelly J, Montcuquet P, Chaigneau L, Villanueva C, Fiteni F, Meneveau N, Perrin S, Voidey A, Monnot T, Pivot X, Limat S
Lien Pubmed
Résumé
AIM: To carry out a cost-minimization analysis including a comparison of the costs arising from first-line treatment by trastuzumab plus docetaxel versus trastuzumab plus paclitaxel in patients with metastatic breast cancer. METHODS: All consecutive patients with human epidermal growth receptor 2-postive metastatic breast cancer who were treated at Besancon University Hospital and Saint Vincent private hospital between 2001 and 2010 by first-line therapy containing trastuzumab plus taxane were retrospectively studied. Economic analysis took into account costs related to drugs, hospitalization, and healthcare travel. RESULTS: Progression-free survival difference between the two treatments was not significant (p = 0.65). First-line treatment by trastuzumab plus taxane was estimated at approximately euro68,000 (p = 0.74). The drug costs represented around 70-75% of the total cost, mainly related to the use of trastuzumab. CONCLUSION: Our economic analysis shows that although the costs of the two trastuzumab plus taxane regimens are similar, they may contribute to the on-going debate about the availability and use of innovative chemotherapy drugs, in particular in human epidermal growth factor receptor 2-positive metastatic breast cancer with new therapies such as trastuzumab-DM1 and pertuzumab.
Référence
J Oncol Pharm Pract. 2014 Oct;20(5):362-8